{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:05:46Z","timestamp":1789733146418,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.waojou.2026.101438","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:00:47Z","timestamp":1788372047000},"page":"101438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns and disease burden of hypereosinophilic syndrome (HES) in the United States: A real-world observational, retrospective cohort study"],"prefix":"10.1016","volume":"19","author":[{"given":"Thanai","family":"Pongdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Eudicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinwei Arnold","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Yanjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2026.101438_bib1","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101438_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13601-019-0277-4","article-title":"Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm","volume":"9","author":"Leru","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.waojou.2026.101438_bib3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.anai.2023.02.022","article-title":"Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization","volume":"130","author":"Hwee","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2026.101438_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.waojou.2026.101438_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101438_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2015.04.002","article-title":"Spectrum of eosinophilic end-organ manifestations","volume":"35","author":"Akuthota","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.waojou.2026.101438_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2026.101438_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.waojou.2026.101438_bib9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101438_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2023.03.011","article-title":"Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis","volume":"151","author":"Wechsler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2026.101438_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cyto.b.21874","article-title":"Lymphocytic variant of hypereosinophilic syndrome: a report of seven cases from a single institution","volume":"100","author":"Hu","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.waojou.2026.101438_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/ijms22020486","article-title":"Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes","volume":"22","author":"Stella","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.waojou.2026.101438_bib13","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/j.jaip.2023.07.026","article-title":"Biologics and hypereosinophilic syndromes: knowledge gaps and controversies","volume":"11","author":"Kuang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101438_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.waojou.2026.101438_bib15","unstructured":"Nucala US Prescribing Information. [updated March 2023; cited September 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125526Orig1s021,761122Orig1s011Corrected_lbl.pdf."},{"key":"10.1016\/j.waojou.2026.101438_bib16","unstructured":"Nucala EU Summary of Product Characteristics. [updated March 2026; cited September 2025] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf."},{"key":"10.1016\/j.waojou.2026.101438_bib17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.waojou.2026.101438_bib18","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41591-026-04315-8","article-title":"Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial","volume":"32","author":"Ogbogu","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.waojou.2026.101438_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2026.101438_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/all.16463","article-title":"Hypereosinophilia and hypereosinophilic syndromes: first findings from a nationwide multicenter cohort","volume":"80","author":"Lef\u00e8vre","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2026.101438_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.waojou.2026.101438_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251318615","article-title":"Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Hua","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.waojou.2026.101438_bib22","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101438_bib24","unstructured":"GSK. FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES). Available at: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-nucala-as-the-first-and-only-biologic-treatment-for-hypereosinophilic-syndrome-hes\/. Last accessed September 2025."}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455126002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455126002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:39:39Z","timestamp":1789731579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455126002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1939455126002711"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2026.101438","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and disease burden of hypereosinophilic syndrome (HES) in the United States: A real-world observational, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2026.101438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"101438"}}